Videos

A panelist discusses how managing chronic insomnia often requires tailored treatments like dual orexin receptor antagonists (DORAs), which offer long-term benefits for sleep maintenance without the risk of tolerance or rebound insomnia, while emphasizing patient counseling and realistic expectations for gradual improvement.

A panelist discusses how the phase 2b ENGAGE-E-001 study highlights Staccato alprazolam as an effective and well-tolerated option for rapid seizure termination, emphasizing its quick onset of action and potential benefits, while also cautioning about adverse effects such as sedation and respiratory depression in certain patients.

Panelists discuss how variable number tandem repeats (VNTR) 3/2 polymorphisms in the FCGRT gene may affect FcRn levels, immunoglobulin G (IgG) half-life, and the effectiveness of intravenous immunoglobulin (IVIg) therapy in chronic inflammatory demyelinating polyneuropathy (CIDP), highlighting early real-world evidence suggesting that genetic testing could help personalize treatment strategies to optimize outcomes for patients based on their specific genotypes.

Panelists discuss how biomarkers, such as neurofilament light chain (NfL), autoantibodies, and inflammatory markers, have potential in enhancing chronic inflammatory demyelinating polyneuropathy (CIDP) diagnosis and treatment monitoring, but emphasize that their use remains experimental, and a comprehensive approach integrating clinical assessments and electrophysiological findings is essential for optimal patient care.

An expert discusses strategies to lower the age of Duchenne muscular dystrophy (DMD) diagnosis, emphasizing the importance of universal newborn screening with the testing of creatine kinase (CK) levels, clinician recognition of motor red flags such as the Gower sign, early neurology referrals, and incorporating CK level testing in cognitive delay evaluations to enable timely therapeutic intervention and improve long-term outcomes.

5 experts in this video

Panelists discuss how the newly FDA-approved continuous subcutaneous levodopa infusion system (foscarbidopa/foslevodopa) offers another advanced treatment option, exploring the ideal candidates for these continuous infusion therapies based on disease characteristics, previous treatment responses, and patient preferences.

Panelists discuss how recent advances in Alzheimer disease, including amyloid-targeting therapies like lecanemab and donanemab, along with the growing role of blood-based biomarkers for early diagnosis and monitoring, are transforming treatment paradigms, enabling disease modification and personalized care while improving accessibility and reducing barriers to diagnosis.

Panelists discuss how the TRAILBLAZER-ALZ-2 trial demonstrates that donanemab significantly reduces amyloid plaques and slows cognitive and functional decline in early Alzheimer disease, with a manageable safety profile and the potential for faster plaque removal compared to other amyloid-targeting therapies.